**Conflict of interest:** The authors declare no conflict of interest.

aCGH

:   array‐comparative genomic hybridization

CNAs

:   copy number alterations

CRGs

:   chromatin remodeling genes

EMGs

:   epigenetic modifiers genes

OS

:   overall survival

PFS

:   progression‐free survival

SNVs

:   single nucleotide variants

TSCA

:   TruSeq® Custom Amplicon

WES

:   whole exome sequencing

WGS

:   whole genome sequencing

Introduction {#ijc32361-sec-0001}
============

Alterations in chromatin remodeling genes (CRGs) have emerged as an important cause of cancer; in particular, the identification of inactivating genetic alterations in the *SMARCB1* gene in rhabdoid tumors (RTs) has highlighted the involvement of the SWI/SNF complex in tumor formation.[1](#ijc32361-bib-0001){ref-type="ref"}, [2](#ijc32361-bib-0002){ref-type="ref"} Indeed, SWI/SNF gene mutations and alterations in other epigenetic modifier genes (EMGs) are thought to occur in 20% of human cancers.[3](#ijc32361-bib-0003){ref-type="ref"}

In neuroblastoma (NB), the most common extracranial solid tumor in children, genetic alterations concern predominantly copy number alterations, with MYCN amplification and segmental chromosome alterations associated with a poor outcome.[4](#ijc32361-bib-0004){ref-type="ref"} Only few genes have been shown to be altered recurrently by genetic events, including *ALK*.[4](#ijc32361-bib-0004){ref-type="ref"} Genes involved in chromatin remodeling such as *ATRX*, *DAXX*, *ARID1A* and *ARID1B* genes have also been shown to be targeted by mutations or structural rearrangements,[5](#ijc32361-bib-0005){ref-type="ref"}, [6](#ijc32361-bib-0006){ref-type="ref"}, [7](#ijc32361-bib-0007){ref-type="ref"}, [8](#ijc32361-bib-0008){ref-type="ref"}, [9](#ijc32361-bib-0009){ref-type="ref"} but the frequency of CRG/EMG alterations has not been described in detail in NB.

The aim of our study was to determine the frequency of CRGs/EMGs variations in NB patients and to correlate findings with clinical parameters and outcome.

Materials and Methods {#ijc32361-sec-0002}
=====================

Study series {#ijc32361-sec-0003}
------------

The study consisted of 283 NB patients, constituting a clinically representative cohort (Table [1](#ijc32361-tbl-0001){ref-type="table"}, Supporting Information Table [S1](#ijc32361-supitem-0002){ref-type="supplementary-material"}; Supporting Information Fig. [S1](#ijc32361-supitem-0001){ref-type="supplementary-material"}).

###### 

Cases showing SNVs, InDels and focal CNAs in CRGs/EMGs in 283 neuroblastoma patients and 30 neuroblastoma cell lines

  Cohort                MYCN status                     Stage                                                      Age at diagnosis                              Analytical technique   Cases with pathogenic/likely pathogenic variations in CRGs/EMGs   Number of pathogenic/likely pathogenic variations in CRGs/EMGs   Pathogenic/likely pathogenic variations in CRG/EMGs   Origin of variations
  --------------------- ------------------------------- ---------------------------------------------------------- --------------------------------------------- ---------------------- ----------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------- ---------------------------
  Patients *n* = 283    MNA *n* = 64; MN‐NA *n* = 219   Stage 4 *n* = 128;Localized *n* = 130; Stage 4s *n* = 25   \<18 months *n* = 159; ≥18 months *n* = 124   WES/WGS *n* = 55       16                                                                18                                                               *ATRX n* = 5                                          2/5 germline; 3/5 Somatic
                                                                                                                                                                                                                                                                                                                           *ARID1B n* = 5                                        Germline
                                                                                                                                                                                                                                                                                                                           *MLL3 n* = 3                                          2/3 Germline; 1/3 Somatic
                                                                                                                                                                                                                                                                                                                           *MLL2 n* = 2                                          Gemline
                                                                                                                                                                                                                                                                                                                           *PBRM1 n* = 1                                         Somatic
                                                                                                                                                                                                                                                                                                                           *ARID1A n* = 1                                        Germline
                                                                                                                                                                                                                                                                                                                           *SMARCA4 n* = 1                                       Germline
                                                                                                                                                                 TSCA *n* = 228         40                                                                42                                                               *ATRX n* = 9                                          Unknown
                                                                                                                                                                                                                                                                                                                           *SMARCA4 n* = 7                                       
                                                                                                                                                                                                                                                                                                                           *MLL2 n* = 1                                          
                                                                                                                                                                                                                                                                                                                           *MLL3 n* = 4                                          
                                                                                                                                                                                                                                                                                                                           *ARID1A n* = 2                                        
                                                                                                                                                                                                                                                                                                                           *ARID2 n* = 4                                         
                                                                                                                                                                                                                                                                                                                           *CHD7 n* = 5                                          
                                                                                                                                                                                                                                                                                                                           *SMARCC1 n* = 1                                       
                                                                                                                                                                                                                                                                                                                           *SMARCA2 n* = 2                                       
                                                                                                                                                                                                                                                                                                                           *SMARCD3 n* = 1                                       
                                                                                                                                                                                                                                                                                                                           *PBRM1 n* = 2                                         
                                                                                                                                                                                                                                                                                                                           *DAXX n* = 1                                          
                                                                                                                                                                                                                                                                                                                           *ARID1B n* = 2                                        
                                                                                                                                                                                                                                                                                                                           *BCL11A n* = 1                                        
  Cell lines *n* = 30   MNA *n* = 22 MN‐NA *n* = 8                                                                                                               TSCA *n* = 30          7                                                                 7                                                                *ATRX n* = 1                                          
                                                                                                                                                                                                                                                                                                                           *MLL2 n* = 2                                          
                                                                                                                                                                                                                                                                                                                           *MLL3 n* = 1                                          
                                                                                                                                                                                                                                                                                                                           *SMARCA4 n* = 2                                       
                                                                                                                                                                                                                                                                                                                           *BCL11A n* = 1                                        

In the 55 samples analyzed by WES/WGS, 7 CRG/EMG genes show at least one variation. In the 248 samples analyzed by the TSCA approach, 14 CRG/EMG genes show a variation. Five genes harbor a variation in NB cell lines.

Patients were treated in French pediatric oncology centers according to the relevant national/international protocols. Written informed consent was obtained from parents/guardians according to national law. Our study was authorized by the ethics committees "Comité de Protection des Personnes Sud‐Est IV", references L07--95/L12--171, and "Comité de Protection des Personnes Ile de France", reference 0811728.

In 55 patients for whom paired normal and tumor tissue was available, whole‐exome sequencing (WES)/whole‐genome sequencing (WGS) techniques were performed, whereas for 248 diagnostic tumor samples, a TruSeq® Custom Amplicon (TSCA) approach was used. Twenty patients are common to the two subsets (Supporting Information Table [S1](#ijc32361-supitem-0002){ref-type="supplementary-material"}).

Furthermore, 30 NB cell lines (Supporting Information Table [S1](#ijc32361-supitem-0002){ref-type="supplementary-material"}) and six germline controls from healthy donors were studied.

To analyze the frequency of CRG/EMG variations, 28 major genes involved in chromatin remodeling processes were selected: *ACTB*, *ACTL6A*, *ACTL6B*, *ARID1A*, *ARID1B*, *ARID2*, *BCL11A*, *BCL11B*, *BCL7A*, *BCL7B*, *BCL7C*, *BRD7*, *BRD9*, *DPF1*, *DPF2*, *DPF3*, *PBRM1*, *PHF10*, *SMARCA2*, *SMARCA4*, *SMARCB1*, *SMARCC1*, *SMARCC2*, *SMARCD1*, *SMARCD2*, *SMARCD3*, *SMARCE1*, *SS18*. Five epigenetic modifier genes, *ATRX*, *DAXX*, *CHD7*, *MLL2 (KMT2D)*, *MLL3 (KMT2C)*, were also selected based to their involvement in a wide variety of human malignancies (Supporting Information Table [S2](#ijc32361-supitem-0002){ref-type="supplementary-material"}).

DNA extraction and aCGH analysis {#ijc32361-sec-0004}
--------------------------------

DNA was extracted from diagnostic tumor samples harboring \>20% of tumor cells using standard procedures. Genomic copy number profiles were determined by aCGH, and MYCN copy number status was confirmed by FISH.

Whole exome/whole genome sequencing {#ijc32361-sec-0005}
-----------------------------------

Paired diagnostic tumor and normal DNA from 55 patients were whole‐genome (*n* = 16) and/or whole‐exome (*n* = 39) sequenced (Illumina® Hiseq2500; average coverage: 80×---100× per sample, respectively[10](#ijc32361-bib-0010){ref-type="ref"}). WGS for eight cases has been reported previously.[10](#ijc32361-bib-0010){ref-type="ref"}

TruSeq® amplicon panel sequencing {#ijc32361-sec-0006}
---------------------------------

Tumor DNA from 248 NB cases and six healthy donor germline DNA samples (negative controls) were analyzed using a TSCA® panel approach covering 33 CRGs/EMGs, (average coverage \>1,500×; TSCA®v1.5, Illumina Inc., San Diego, CA; Supporting Information Table [S2](#ijc32361-supitem-0002){ref-type="supplementary-material"}).

Bioinformatics analysis {#ijc32361-sec-0007}
-----------------------

Bioinformatics approaches depended on the genetic alteration (single nucleotide variations \[SNVs\]), small or large InDels; focal or extended copy number alterations (CNAs) and the sequencing technique.

Whole‐exome and whole‐genome sequencing analyses {#ijc32361-sec-0008}
------------------------------------------------

The WGS/WES sequencing raw reads were mapped to the reference human genome using BWA (assembly GRCh37/hg19)[11](#ijc32361-bib-0011){ref-type="ref"}, [12](#ijc32361-bib-0012){ref-type="ref"} followed by analysis of the exons of the 33 CRGs/EMGs (Supporting Information Table [S2](#ijc32361-supitem-0002){ref-type="supplementary-material"}).

SNVs/InDels \<30 bp were called using GATK\'s HaplotypeCaller v3.5 algorithm.[12](#ijc32361-bib-0012){ref-type="ref"}, [13](#ijc32361-bib-0013){ref-type="ref"} The Manta tool (1.0.3) was used to detect structural variations and large InDels.[14](#ijc32361-bib-0014){ref-type="ref"} All SNVs/small InDels with a VAF \>20% were retained.

Tumor copy number profiles were calculated with FREEC (0.9) using constitutional DNA as reference,[15](#ijc32361-bib-0015){ref-type="ref"}, [16](#ijc32361-bib-0016){ref-type="ref"}, [17](#ijc32361-bib-0017){ref-type="ref"} with annotations of CRGs/EMGs to highlight focal variations.[18](#ijc32361-bib-0018){ref-type="ref"}

Genetic variations were termed "somatic" if no evidence of these variations was observed in the constitutional reads.

TSCA® analysis {#ijc32361-sec-0009}
--------------

The TSCA® sequencing reads were mapped to the reference human genome with Bowtie.[19](#ijc32361-bib-0019){ref-type="ref"} To prevent strand or coverage bias due to noncomplete overlap of forward (FW) and reverse (RV) reads of amplicons, the bam files were split to FW and RV read bam(s).

An adapted approach was developed to enable variant calling in TSCA® data.[20](#ijc32361-bib-0020){ref-type="ref"}

For SNVs, coverage analysis was performed at each base position (GATK DepthOfCoverage). The background of noise (variability) of each amplicon was then analyzed in the six negative controls.

All possible variants (e.g., ref = A; A \> T, A \> C, A \> G, A \> ‐) and their alternative allele fraction (AF) were calculated for each position, and Fisher\'s exact two‐sided tests with a Bonferroni correction were performed to compare percentages of variant allele fraction (VAF) for a given base between a case and the negative controls. Significant variations were filtered‐in in case of an increase in the percentage of variant base (5% significance level). Only positions with total depth of coverage higher than 100× were considered for variant analysis. All SNVs/small InDels with a VAF \>5% were retained.

Recurrent variants and variants with VAF \>20% detected in more than two samples were filtered‐out as they most likely indicate polymorphisms. Finally, FW and RV results were confronted and ambiguous cases were filtered‐out.

Amplicon InDels Hunter tool was used to detect large InDels.[21](#ijc32361-bib-0021){ref-type="ref"} Recurrent InDels detected in more than two samples were filtered‐out.

For focal CNAs, the depth of coverage of targeted regions was calculated for FW and RV bams (GATK DepthOfCoverage). For each sample, the coverage of each amplicon was normalized by the median of sample depth followed by comparison to negative controls. The FW and RV normalized data were then merged to reconstruct copy number profiles. The copy number profile obtained from TSCA data using our in‐house developed pipeline was also confirmed by another technique ONCOCNV, a method that includes a multifactor normalization with respect to library size, CG‐content and target length to detection of large copy number changes from amplicon deep sequencing data.[22](#ijc32361-bib-0022){ref-type="ref"}

Finally, the list of SNVs and InDels was manually curated and visually inspected in IGV (Integrated Genome Viewer).[23](#ijc32361-bib-0023){ref-type="ref"}

Variant annotation, prioritization and classification {#ijc32361-sec-0010}
-----------------------------------------------------

All SNVs/InDels were annotated using SnpEff/SnpSift.[24](#ijc32361-bib-0024){ref-type="ref"} Annotation was performed using canonical transcripts and publicly available databases dbSNPv150,[25](#ijc32361-bib-0025){ref-type="ref"} gnomADv2.0.2 (<http://gnomad.broadinstitute.org/>),[26](#ijc32361-bib-0026){ref-type="ref"} COSMICv74,[27](#ijc32361-bib-0027){ref-type="ref"} ClinVar(25‐02‐2018),[28](#ijc32361-bib-0028){ref-type="ref"} dbNSFPv2.9.3[18](#ijc32361-bib-0018){ref-type="ref"} and known cancer Hotspots.[29](#ijc32361-bib-0029){ref-type="ref"} Loss of function (LoF) assessment was performed using the snpEff tool. SNVs/InDels were discarded as benign/likely benign/polymorphic based on population minor allele frequency (popmax) ≥0.1% from gnomAD database. However, SNVs/inDels reported as pathogenic/likely pathogenic in ClinVar were retained. In addition to COSMIC annotations, six prediction algorithms VEST3,[30](#ijc32361-bib-0030){ref-type="ref"} MetaSVM,[31](#ijc32361-bib-0031){ref-type="ref"} REVEL,[32](#ijc32361-bib-0032){ref-type="ref"} MutationTaster,[33](#ijc32361-bib-0033){ref-type="ref"} M_CAP[34](#ijc32361-bib-0034){ref-type="ref"} and CADD[35](#ijc32361-bib-0035){ref-type="ref"} were used to classify all likely protein‐altering SNVs/InDels (frameshift, nonsense, splice donor/acceptor, nonsynonymous and in‐frame insertions/deletions) as pathogenic, likely pathogenic. The flowchart of variant classification is indicated in Supporting Information Figure [S4A](#ijc32361-supitem-0001){ref-type="supplementary-material"} and the prediction score thresholds in Supporting Information Figure [S4B](#ijc32361-supitem-0001){ref-type="supplementary-material"}.

SNVs/small InDels validation {#ijc32361-sec-0011}
----------------------------

All retained SNVs/small InDels with VAF \>20% were confirmed by Sanger sequencing. SNVs with VAF \<20% were validated by NGS/targeted sequencing in an independent second experiment.[36](#ijc32361-bib-0036){ref-type="ref"}

Comparison of CRG/EMG variation frequencies between NB and gnomAD reference cohort {#ijc32361-sec-0012}
----------------------------------------------------------------------------------

We compared the CRG/EMG variation frequencies from the NB cohort (Supporting Information Table [S3](#ijc32361-supitem-0002){ref-type="supplementary-material"}) with those reported in a large unrelated population (gnomAD database; *n* = \~123,000). The gnomAD VCF file was intersected with the CRG/EMG TSCA® panel bed file and the corresponding subset of variants from gnomAD were extracted. Using the same approach as in the NB cohort, SNVs/InDels from gnomAD were annotated/classified into pathogenic/likely pathogenic and their frequency was calculated by dividing the sum of the allele count by the median of total alleles. To compare the frequencies of CRG/EMG variations in the NB *vs*. the control cohort, for each gene an Odds Ratios was calculated: OR = (NB cases with pathogenic/likely pathogenic variant/cases without pathogenic or likely pathogenic variant)/(gnomAD control with pathogenic or likely pathogenic variant/gnomAD control without pathogenic or likely pathogenic variant) along with 95% confidence intervals. *p*‐Value and OR were obtained using two‐sided Fisher\'s test performed in R.[37](#ijc32361-bib-0037){ref-type="ref"}

Statistical analysis {#ijc32361-sec-0013}
--------------------

Correlation analyses using chi‐squared test was done with MedCalc (Medical Calculator 13.3.0.0). Progression‐free survival (PFS) and overall survival (OS) were estimated using the Kaplan--Meier method, and comparisons were made using log‐rank tests.

Western blot {#ijc32361-sec-0014}
------------

Immunoblots were done as reported previously using monoclonal rabbit SMARCA4/BRG1 (EPR3912, \#GTX62750, Genetex, Irvine, CA) and HRP‐conjugated GAPDH (\#HRP‐60004, ProteinTech, Rosemont, IL) antibodies.

Results {#ijc32361-sec-0015}
=======

Genetic variations of CRGs/EMGs detected in 283 NB patients and in 30 NB cell lines {#ijc32361-sec-0016}
-----------------------------------------------------------------------------------

In a cohort of 283 patients studied by WGS/WES (*n* = 35) or by TSCA® (*n* = 228), or both (*n* = 20), pathogenic/likely pathogenic genetic variations (focal CNAs, InDels, SNVs) in at least one CRG/EMG were identified in 56/283 cases (20%). Altogether 60 pathogenic/likely pathogenic genetic variations were identified (Table [1](#ijc32361-tbl-0001){ref-type="table"}, Fig. [1](#ijc32361-fig-0001){ref-type="fig"} and Supporting Information Table [S3](#ijc32361-supitem-0002){ref-type="supplementary-material"}). The most frequently altered genes were *ATRX*, *SMARCA4*, *MLL3* and *ARID1B*.

![Genetic variations in chromatin remodeling and epigenetic modifier genes across a series of 283 NB patients and 30 NB cell lines analyzed by TSCA and/or WGS/WES approaches. In the lower part of the figure, genes found to be altered (*n* = 14) are arranged in rows; cases for whom a genetic variation is detected in the studied genes (*n* = 56) are arranged in columns, respectively. The 60 SNVs, InDels, and focal CNAs detected in the 56 cases are represented by colored cases. Double events (SNV/inDels and LOH) are represented by colored cases surrounded by a black square. In the lower part of the graph, the 9 SNVs, InDels and CNAs detected in 7 NB cell lines are represented. The overall frequencies are indicated in the upper half of the figure. Nonsynonymous SNVs are represented in green, stop‐gain SNVs are represented in red, InDels are represented in blue, focal CNA in purple and large deletions in brown. The right data grid summarizes clinical information of each neuroblastoma sample.](IJC-145-2781-g001){#ijc32361-fig-0001}

*ATRX* was targeted by focal CNAs, small InDels and SNVs in 6, 2 and 6 cases, respectively (Supporting Information Table [S3](#ijc32361-supitem-0002){ref-type="supplementary-material"} and Fig. [1](#ijc32361-fig-0001){ref-type="fig"}). *SMARCA4* was altered by 6 SNVs/InDel, 1 focal CNA and 1 large deletion. *MLL3* was targeted by SNVs in seven cases (Supporting Information Table [S3](#ijc32361-supitem-0002){ref-type="supplementary-material"}, Fig. [1](#ijc32361-fig-0001){ref-type="fig"}). *ARID1A* and *ARID1B* genes were altered in altogether 10/283 (3.5%) cases, with two SNVs and one InDel in *ARID1A* and five inDels and two SNVs in *ARID1B*.[9](#ijc32361-bib-0009){ref-type="ref"}

Variations in two different CRGs/EMGs were observed in three cases (Supporting Information Table [S3](#ijc32361-supitem-0002){ref-type="supplementary-material"}, in bold; Fig. [1](#ijc32361-fig-0001){ref-type="fig"}), targeting *MLL3* and *ATRX*, *MLL3* and *ARID1B*, and *PBRM1* and *ATRX*, respectively.

Double events encompassing both SNV/small InDels, focal CNAs and additional LOH/copy number loss of the same gene were observed in six cases (Fig. [1](#ijc32361-fig-0001){ref-type="fig"}). The *SMARCA4* gene was targeted by double events in three cases *(*NBSW80, NBSW251 and NBSW77) with either a SNV and/or InDel (3 bp) in the presence of only 1 copy of the *SMARCA4* gene, corresponding to focal deletions (Figs. [2](#ijc32361-fig-0002){ref-type="fig"} *a* and [2](#ijc32361-fig-0002){ref-type="fig"} *b*).

![Example of double event detection (SNV and copy number loss in *SMARCA4* gene) by TSCA and aCGH data analysis in NBSW80. (*a*) The IGV profile from TSCA analysis revealed the presence of one SNV in *SMARCA4* (C\>T; chr19: 11132500) gene with variant allele fraction of 87%. (*b*) The comparison between the copy number profiles obtained by TSCA revealed a second event with copy number loss in the *SMARCA4* gene.](IJC-145-2781-g002){#ijc32361-fig-0002}

Case NBSW165 showed a loss of one copy and a focal CNA covering a region from EX2 to EX9 of the second copy of *ATRX* (Fig. [1](#ijc32361-fig-0001){ref-type="fig"}; Supporting Information Table [S3](#ijc32361-supitem-0002){ref-type="supplementary-material"}). A copy number loss involving the *PBRM1* gene is observed in case NBSW23; a somatic SNV is also observed in the same gene (Fig. [1](#ijc32361-fig-0001){ref-type="fig"}).

In another patient (NBSW26) presenting with speech delay, attention deficit and hyperactivity disorder as well as an adrenal stage *INSS stage 1*, *INRG L1* NB diagnosed at 4 years of age, a germline deletion of 1.7 Mb at chromosome band 19p13.2 (chr19:10462524--12157782) was detected (Supporting Information Fig. [S2](#ijc32361-supitem-0001){ref-type="supplementary-material"}). The germline deleted region encompassing among others the *SMARCA4* gene was confirmed by aCGH on peripheral blood lymphocytes (Supporting Information Table [S2](#ijc32361-supitem-0002){ref-type="supplementary-material"}).

Targeted TSCA® sequencing of the 33 CRGs/EMGs was performed in 30 NB cell lines (Supporting Information Table [S1](#ijc32361-supitem-0002){ref-type="supplementary-material"}). Nine variations were detected in seven NB cell lines (Table [1](#ijc32361-tbl-0001){ref-type="table"}, Supporting Information Table [S3](#ijc32361-supitem-0002){ref-type="supplementary-material"}, Fig. [1](#ijc32361-fig-0001){ref-type="fig"}), most frequently targeting *SMARCA4* (3 cases), *MLL2* (2 cases) and *MLL3* (2 cases) (Fig. [1](#ijc32361-fig-0001){ref-type="fig"}, Supporting Information Table [S3](#ijc32361-supitem-0002){ref-type="supplementary-material"}).

Interestingly, a genetic event consisting of partial loss of the *MLL2* gene was detected in the NB cell line CLB‐Re (Fig. [3](#ijc32361-fig-0003){ref-type="fig"} *a*). SNP6 analysis in the same NB cell line revealed a large region of copy number loss in chr12 encompassing the *MLL2* gene at the position chr12:49449107--58196639, confirming the observation obtained by TSCA sequencing (Fig. [3](#ijc32361-fig-0003){ref-type="fig"} *b*).

![Partial loss event detected in *MLL2* gene in CLB‐Re NB cell line. (*a*) The copy number profile obtained by TSCA shows the presence of a partial loss starting in *MLL2* gene. (*b*) SNP6.0 array‐based copy number encompassing the Chromosome 12 confirms the presence of a large loss with a breakpoint within the *MLL2* gene.](IJC-145-2781-g003){#ijc32361-fig-0003}

In the SKNFI cell line, a double event (SNV and LOH) was observed in *SMARCA4* (Figs. [4](#ijc32361-fig-0004){ref-type="fig"} *a* and [4](#ijc32361-fig-0004){ref-type="fig"} *b*). The absence of expression of *SMARCA4* was confirmed by expression analysis and western blot. On the other hand, expression of SMARCA4 was maintained in the SKNSH cell line which harbors a single SNV event in this gene (Figs. [4](#ijc32361-fig-0004){ref-type="fig"} *c* and [4](#ijc32361-fig-0004){ref-type="fig"} *d*).

![Example of double event (LOH and SNV in *SMARCA4* gene) in SKNFI NB cell line. (*a*) The IGV profile from TSCA ampliseq analysis revealed the presence of one SNV in *SMARCA4* gene (C\>T; Chr19: 11170813) with variant allele fraction of 99%. (*b*) The copy number profile obtained by TSCA shows the presence of a second event with copy number loss in the same gene. (*c*) Immunoblot of SMARCA4 expression in different neuroblastoma and nonneuroblastoma cell lines. BIN67: Small cell carcinoma of the ovary of hypercalcemic type; A549: lung carcinoma; SKNSH, SKNFI, SKNBE(2C), IMR32 and TGW: neuroblastoma. (*d*) SNVs, inDels and focal CNAs identified in *SMARCA4* gene mapping functional domains in patients enrolled in the study.](IJC-145-2781-g004){#ijc32361-fig-0004}

Germline *vs*. somatic occurrence of variations {#ijc32361-sec-0017}
-----------------------------------------------

Altogether, among the 60 pathogenic/likely pathogenic CRG/EMG variations, the variation occurred at a somatic level in five cases, targeting *ATRX*, *PBRM1* or *MLL3*, whereas a germline variation could be confirmed in 13 other cases, targeting *ARID1B*, *MLL3*, *MLL2*, *ATRX*, *ARID1A* and *SMARCA4* (Supporting Information Table [S3](#ijc32361-supitem-0002){ref-type="supplementary-material"}; Fig. [1](#ijc32361-fig-0001){ref-type="fig"}). For the remaining 42 variations detected in tumor samples without paired germline material available, a distinction between germline and somatic variation could not be made.

We then compared the frequencies of pathogenic/likely pathogenic SNVs/inDels of the 33 studied CRGs/EMGs in the NB cohort to those observed in gnomAD as a control cohort. The analysis revealed a significantly higher frequency of variations (*p* \< 0.05 after Bonferroni correction) in two CRGs, *SMARCA4* (OR 4.49, 95% CI: 1.63--9.97, *p* = 0.038) and *ATRX* (OR 3.44, 95% CI: 1.46--6.91, *p* = 0.043) in NB cases when compared to gnomAD, independent of whether the observed SNVs were of known germline, somatic or unknown origin, indicating an enrichment for variations in the genes *SMARCA4* and *ATRX* in NB cases. All other CRGs/EMGs included in our study were not altered with a higher frequency than in the general population (Supporting Information Table [S4](#ijc32361-supitem-0002){ref-type="supplementary-material"}).

Potential functional impact {#ijc32361-sec-0018}
---------------------------

The potential functional impact of the observed variations was analyzed *in silico*. For a given variation, within the studied gene, the localization of the amino acid change was studied with regards to domains of functional importance for chromatin remodeling or highly conserved domains but with unknown function.

Among the 30 variations detected in CRGs, 12 variations were localized in these domains (9 SNVs, 1 focal CNA, 1 InDel and 1 large inDel; Supporting Information Table [S3](#ijc32361-supitem-0002){ref-type="supplementary-material"}). Their position was then analyzed with regards to protein‐specific domains (DNA binding, bromodomain, histone binding, protein--protein interaction domains). In the *SMARCA4* gene, four identified variations mapped to these functional domains (Fig. [4](#ijc32361-fig-0004){ref-type="fig"} *d*), including three missense point mutations in the ATPase domain of *SMARCA4* gene (Fig. [4](#ijc32361-fig-0004){ref-type="fig"} *d*).

Among the 30 variations observed in EMGs, 12 variations were localized in domains of functional importance (10 SNVs, 1 focal CNA, 1 InDel; Supporting Information Table [S3](#ijc32361-supitem-0002){ref-type="supplementary-material"}).

Overall, among all 60 variations observed in CRGs/EMGs, 24 mapped to domains of functional importance at a protein level (Supporting Information Table [S3](#ijc32361-supitem-0002){ref-type="supplementary-material"}).

Correlation of CRGs/EMGs variations with clinical parameters {#ijc32361-sec-0019}
------------------------------------------------------------

There were no statistically significant correlations between the presence of a CRG/EMG variation and the main clinical prognostic parameters of NB (data not shown). Furthermore, among patients whose tumors were analyzed by WGS (*n* = 8),[10](#ijc32361-bib-0010){ref-type="ref"} the presence of CRG/EMG variations, was not associated with an overall increase in the tumor mutational burden (data not shown).

A statistically significant poorer overall survival was observed for patients whose tumors harbored CRG/EMB variations in the overall cohort (Supporting Information Fig. [S3A](#ijc32361-supitem-0001){ref-type="supplementary-material"}). However, there was no statistically significant difference of overall survival between the two patient groups in patient subgroups defined by age, stage or MYCN status, nor among all high‐risk patients only (*n* = 124; Supporting Information Fig. [S3C](#ijc32361-supitem-0001){ref-type="supplementary-material"}). Furthermore, no statistically significant difference in PFS was observed (Supporting Information Fig. [S3B](#ijc32361-supitem-0001){ref-type="supplementary-material"}).

Discussion {#ijc32361-sec-0020}
==========

Recent reports have highlighted chromatin remodeling as an important player in oncogenesis, with the main mechanisms of action consisting in tumor suppression, but variations in CRG/EMGs might also play a role in oncogenesis via gain of function.[38](#ijc32361-bib-0038){ref-type="ref"}, [39](#ijc32361-bib-0039){ref-type="ref"} CRG alterations have previously been identified in NB patients, targeting *ARIDs*, *ATRX*, *DAXX* or *SMARCA4*.[7](#ijc32361-bib-0007){ref-type="ref"}, [8](#ijc32361-bib-0008){ref-type="ref"}, [9](#ijc32361-bib-0009){ref-type="ref"}, [40](#ijc32361-bib-0040){ref-type="ref"}, [41](#ijc32361-bib-0041){ref-type="ref"}

Our study now focused on the genetic status of 33 CRGs/EMGs in tumor samples of 283 NB patients. Altogether, CRG/EMG variations (focal CNA, InDels, SNVs) were identified in 56 cases (20%), mapping to CRG/EMG functional domains in 8.4% (24/283) of cases and most frequently targeting *ATRX*, *SMARCA4*, *MLL3* and *ARID1B*. Other CRGs and many more EMGs, not covered by the panel used in this targeted analysis, exist throughout the genome,[42](#ijc32361-bib-0042){ref-type="ref"} and thus it is possible that variations targeting other CRG/EMGs not taken into account in our study might also be present in the analyzed samples.

In NB, *ATRX* alterations have been associated with activated alternative lengthening of telomere (ALT).[8](#ijc32361-bib-0008){ref-type="ref"} In our study, 5% (14/283) of cases showed an *ATRX* variation (SNV/InDel or focal CNA). Further studies will be required to establish the role of these variations on patient survival.

The *MLL3* gene is rarely altered in NB, with two *MLL3* variations (A293V and P309L) reported outside of annotated protein domains.[43](#ijc32361-bib-0043){ref-type="ref"} In our cohort, seven missense SNVs were detected, four of them within MLL3 functional domains.

Alterations in *ARID1A*/*ARID1B* have been described in 11% of NB patients,[9](#ijc32361-bib-0009){ref-type="ref"} with the presence of variations in a single allele of *ARID1A*/*ARID1B* possibly corresponding to a dominant tumor suppressor.[41](#ijc32361-bib-0041){ref-type="ref"} Ten cases showed *ARID1A*/*ARID1B* variations, with two SNV/inDels occurring in functional domains.

Altogether, among the 56 cases with CRG/EMG variations, four patients harbored somatic and 12 showed germline variations. For the remaining 40 cases, due to the absence of paired germline DNA, it could not be established whether the observed variations were somatic or might concern private constitutional polymorphisms. Yet constitutional variations of potential functional impact might also be of oncogenic importance.

Indeed, germline events in CRGs such as *SMARCB1*, *SMARCA4* or *SMARCE1* have been described as predisposition syndromes for other cancer types, including RT.[1](#ijc32361-bib-0001){ref-type="ref"} In our series, germline events in CRGs/EMGs were observed in 23.6% (13/55) of patients with available germline material.

In RT, the recurrent germline loss of one *SMARCB1* allele followed by somatic loss of the second allele indicates a classic tumor suppressor, with loss of critical subunits of SWI/SNF.[2](#ijc32361-bib-0002){ref-type="ref"} Given the possible suppressor behavior of CRG/EMGs, we searched for double events possibly causing loss of function, with double events identified in 2.1% (6/283) of patients, most frequently in *SMARCA4* (3/283).

*SMARCA4* has been shown to play a role in the oncogenesis of different tumors and thus are not specific to NB. Indeed, germline alterations in SMARCA4 conferring predisposition to SCCOHT and RT.[39](#ijc32361-bib-0039){ref-type="ref"}, [44](#ijc32361-bib-0044){ref-type="ref"}, [45](#ijc32361-bib-0045){ref-type="ref"} At a somatic level, missense point mutations in *SMARCA4* mapping to the ATPase domain might cause loss of direct binding between BAF and PRC1 which could contribute to oncogenesis or epigenetic plasticity during tumor development.[46](#ijc32361-bib-0046){ref-type="ref"} Such *SMARCA4* missense point mutations have been described in medulloblastoma.[47](#ijc32361-bib-0047){ref-type="ref"}, [48](#ijc32361-bib-0048){ref-type="ref"}

In our study, 5/8 *SMARCA4* variations concerned missense point mutations. Although it has been suggested that *SMARCA4* might function as an oncogene in NB, and the overexpression of SMARCA4 in Stage 4 NB patients is associated with poorer outcomes,[49](#ijc32361-bib-0049){ref-type="ref"} the functional impact of genetic variations can be difficult to determine without in‐depth functional studies which are beyond the scope of this article.

Even though the somatic or germline origin of *SMARCA4* variations in our study remained undetermined, our data suggest that variations in *SMARCA4* might play a role in the oncogenesis of NB, and several arguments now underline its role. First, we describe a case of NB within the context of a germline deletion encompassing *SMARCA4*. Second, our findings highlight a significantly higher frequency of variations in *SMARCA4* in NB cases when compared to the gnomAD reference population. Third, we identified four NB cases showing double events targeting *SMARCA4*. In addition, a double event (stop‐gain variation and LOH) of *SMARCA4* was observed in the SKNFI NB cell line causing the absence of SMARCA4 expression.

Further functional studies are needed for a deeper understanding of *SMARCA4* variations in NB in order to guide the development of more effective therapies.

Altogether, our data demonstrate CRG/EMG variations with likely functional impact in 8.4% (24/283) of all NB patients.

Although no difference in PFS between cases with or without CRG/EMG variations was observed, a poorer overall survival in cases harboring CRG/EMG variations was observed. This suggests that cases harboring CRG/EMG variations might present more aggressive disease or that salvage treatment used at relapse might potentially be more efficient in cases showing no CRG/EMG variation. Correlations between the presence of variations in CRG/EMG and other genetic factors associated with poor outcome in NB should be determined in future studies and larger series, such as the overall mutational burden[50](#ijc32361-bib-0050){ref-type="ref"} or factors contributing to a mechanistical classification of NB including mutations of the RAS:MAPK pathway and telomere maintenance mechanisms.[51](#ijc32361-bib-0051){ref-type="ref"}

New treatment strategies are necessary for patients with high‐risk NB, and our data further highlight the potential interest of drugs modulating chromatin remodeling processes. Histone deacetylase inhibitors (HDACi) or DNA methyltransferase inhibitors were the first epigenetic compounds to reach clinical trials with potential benefits in some patients with CRG/EMG variations.[52](#ijc32361-bib-0052){ref-type="ref"} Further preclinical development of therapeutic approaches involving CRGs/EMGs and in particular *SMARCA4* will be warranted.

Supporting information
======================

###### 

**Figure S1:** Kaplan--Meier curves and log‐rank analysis for (OS) overall survival of 283 NB cases according to the main clinical parameters for NB (A, according to MYCN status; B, according to INSS disease stages; C, according to age at the diagnosis). (A) OS for MYCN amplified NB patients *vs*. MYCN non amplified patients. MYCN amplification: *n* = 64 (23%). The 5‐year overall survival for patients with MYCN amplified NB was 24% *vs*. 84% for patients with non‐MYCN amplified. (B) OS for stage 4 patients *vs*. stage 4 s *vs*. Loc NB patients. INSS stage 4: *n* = 152 (53.7%); INSS stage 4 s: *n* = 25 (8.8%); INSS Localized disease: *n* = 130 (45%). (C) OS for patients with an age at diagnosis \<18 months *vs*. patients with an age at diagnosis ≥18 months. \>18 months: *n* = 159 (56%); ≥18 months: *n* = 124 (44%).

**Figure S2:** Large germline deletion (1.7 Mb) encompassing *CDKN2D*, *ILF3*, *SMARCA4* and *CNN1* genes is detected in chr19 (chr19:10462524--12,157,782) in the patient NBSW26. No genes of interest are included in the 2 small deletions detected at the end of chr19 (chr19:52271802--52,588,019 and chr19:55294257--55,370,554).

**Figure S3:** (A) Kaplan--Meier curves and log‐rank analysis for overall (OS) and progression‐free survival (PFS) (B) of 283 NB cases comparing tumors with a CRG/EMG variation and tumors without CRG/EMG variations. A statistically significant lower OS was observed for patients whose tumors harbor CRG/EMG variations (5 year OS, 58% *vs*. 74%, *p* = 0.0302, log‐rank test) (C) Kaplan--Meier curves and log‐rank analysis for overall survival (OS) of 124 high‐risk NB patients included in the cohort comparing tumors with CRG/EMG variation and tumors without CRG/EMG variations. A statistically significant difference between the two patient groups was observed.

**Figure S4:** (A) Variation (SNVs/InDels) annotation, prioritization and classification workflow. (B) A table with six *in silico* prediction tools/algorithms used to prioritize and classify variations (SNVs) into pathogenic/likely pathogenic and variation of unknown significance (VUS).

###### 

Click here for additional data file.

###### 

**Table S1:** summary of all studied NB cases. (A) NB patients. NB patients were chosen to substitute a clinically representative cohort: (INSS stage 4: n = 128 (45%); INSS stage 4 s: n = 25 (8.8%); localized disease, n = 130 (45%); MYCN amplification: n = 64 (23%). (B) NB cell lines. Legend A: DOD, dead of disease; MD, Missing Data; NA, not applicable. Genomic profile: MNA, MYCN amplification; MN‐NA, MYCN Not‐amplified. Genomic profile: 17q G, 17q gain; 1pD, 1p deletion. Technique of sequencing: WGS, Whole Genome Sequencing; WES, Whole Exome Sequencing; TSCA, TruSeq® Custom Amplicon. NB high‐risk patient subgroup has been defined according to the current SIOPEN treatment strategy. Legend B: F: female; M: male; Loc: localized; MD, missing data. MYCN status: MNA, MYCN amplification; MN‐NA, MYCN Not‐amplified; ALK mutation, wt: wild type; ALK status: ALK‐NA, ALK not amplified; ALK A, ALK amplified; Genomic profile: 17q G, 17q gain; 1pD, 1p deletion

**Table S2:** TSCA® design covering 33 CRGs/EMGs, consisting of a total of 1,070 amplicons (262,756 bp) (average coverage: \<1,500X; TSCA®v1.5, Illumina Inc., San Diego, CA, USA). All exonic regions of targeted genes are completely covered except for 240 bp of exonic regions for *SMARCC2*, *DAXX* and *SMARCC1* genes, indicated in bold in the table.

**Table S3:** Summary of all SNV, InDels and focal CNAs detected in NB cases. (A) SNVs/InDels/focal CNAs detected in NB patients. (B) SNVs/InDels/focal CNAs detected in NB cell lines. Legend: For a given coordinate, the base corresponding to the reference genome (Human Genome Browser, <http://genome.ucsc.edu/>; hg19) is indicated. In bold: NB cases showing multiple variations in CRGs/EMGs. Abbreviations: D, Deleterious; T, Tolerated; NA, Not available; AA, amino acid; CNA copy number alteration. Technique of sequencing: WGS, Whole Genome Sequencing; WES, Whole Exome Sequencing; TSCA, TruSeq® Custom Amplicon.

**Table S4:** Odds ratios and Fisher\'s Exact test results testing for significance of the excess of pathogenic or likely pathogenic SNVs and InDels in NB cases *vs*. gnomAD controls (Fisher\'s Exact test level of significance = 0.05)

###### 

Click here for additional data file.
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